Tharimmune, INC Form 4 insider transactions

Director Gary Stetz of Canton Strategic Holdings, Inc. reported the sale of 100,351 shares of common stock across multiple transactions in May 2026.

Tharimmune's Chief Operating Officer, Sanam Parikh, acquired 5,000 stock options exercisable at $3.075 per share, increasing total beneficial ownership to 55,000 options.

Tharimmune Director James Gordon Liddy acquired 5,000 stock options with an exercise price of $3.075, increasing his total beneficial ownership of derivative securities to 55,000.

Tharimmune's Executive Chairman, Vincent S LoPriore, was granted 90,000 stock options with an exercise price of $3.075, effective November 3, 2025.

Tharimmune, Inc. Director Nancy Davis Rickel acquired 5,000 stock options at an exercise price of $3.075.

Tharimmune, Inc. Director Gary S. Stetz acquired 32,500 stock options with an exercise price of $3.075, bringing his total beneficial ownership to 82,500 options.

Gravitas Capital LP, a 10% owner and director of Tharimmune, Inc., reported the acquisition of 90,000 stock options with an exercise price of $3.075.

Tharimmune, Inc. Director Thomas Clay Kahler acquired 17,500 stock options with an exercise price of $3.075 per share.

Tharimmune, Inc. CEO Sireesh Appajosyula reported the acquisition of 20,000 stock options exercisable at $3.075 per share.

Tharimmune, Inc. Director Sanam Parikh was granted 50,000 stock options with an exercise price of $1.33, pursuant to a Rule 10b5-1 plan.

Tharimmune, Inc. CEO Sireesh Appajosyula was granted 90,000 stock options with an exercise price of $1.33, vesting over two years.

Tharimmune, Inc. Director Kelly Anderson reported the acquisition of 6,300 shares of common stock on June 23, 2025, as part of the company's 2023 Omnibus Equity Incentive Plan.

Gravitas Capital LP, a 10% owner, director, and Executive Chairman of Tharimmune, Inc., has increased its beneficial ownership in the company through a direct purchase of common stock.

Tharimmune, Inc. Director Sanam Parikh has acquired 1,000 shares of common stock, increasing their beneficial ownership to 1,770 shares.

Tharimmune, Inc.'s Chief Executive Officer and Director, Sireesh Appajosyula, has increased his direct beneficial ownership in the company through two separate stock acquisitions totaling 61,496 shares.

Director Sanam Parikh of Tharimmune, Inc. reports the acquisition and disposal of 770 shares of common stock on May 15, 2025.

Tharimmune CEO Randy Milby was granted options to purchase 80,958 shares of common stock on January 13, 2025.

Sireesh Appajosyula, Chief Operating Officer of Tharimmune, Inc., was granted options to purchase 52,875 shares of common stock on January 13, 2025.

Tharimmune CEO Randy Milby purchased 4,600 shares of common stock at $2.12 per share on December 19, 2024.

A Tharimmune Inc. executive, Sireesh Appajosyula, has acquired 5,000 shares of common stock at a price of $2.0192 per share.

Tharimmune CEO Randy Milby recently purchased additional shares of the company's common stock, increasing his beneficial ownership.

Sireesh Appajosyula, Chief Operating Officer of Tharimmune, Inc., recently acquired 5,000 shares of common stock at a price of $1.93 per share.

Sireesh Appajosyula, Chief Operating Officer of Tharimmune, Inc., recently purchased 5,000 shares of the company's common stock at a price of $1.93 per share.

Director Kelly Anderson receives options to purchase 2,353 shares of Tharimmune common stock, according to a recent SEC Form 4 filing.

Director Leonard Mazur of Tharimmune, Inc. reports the acquisition of options to purchase 2,353 shares of common stock on August 9, 2024.

Sireesh Appajosyula, Chief Operating Officer of Tharimmune, Inc., was granted options to purchase 38,087 shares of common stock on August 9, 2024.

Director Lynne A. Bui was granted options to purchase 2,353 shares of Tharimmune, Inc. common stock on August 9, 2024, under the company's 2023 Omnibus Equity Incentive Plan.

Tharimmune, Inc. CEO Randy Milby was granted options to purchase 57,707 shares of common stock on August 9, 2024.